DHPA is used in combination with estradiol enantate (E2-EN) or estradiol benzoate butyrate (EBB) as a once-monthly combined injectable contraceptive for women in Latin America, Hong Kong, and Singapore. It was also previously marketed for use alone in Italy. DHPA has reportedly been used to treat acne. E2-EN/DHPA has been said to be used by transgender women in some places of South America as feminizing hormone therapy . Available forms The following forms of DHPA in combination with an estrogen are or have been available for use: * 150 mg DHPA and 10 mg estradiol enantate (brand names Perlutal, Topasel, many others) * 75 mg DHPA and 5 mg estradiol enantate (brand names Anafertin, Patector NF, Yectames) * 120 mg DHPA and 10 mg estradiol enantate (brand names Unalmes, Yectuna) * 75 mg DHPA and 10 mg estradiol enantate (brand name Ova Repos; discontinued) * 150 mg DHPA and 10 mg estradiol benzoate butyrate (brand names Neolutin N, Redimen, Soluna, Unijab) A 90 mg DHPA and 6 mg estradiol enantate formulation was also studied, but was never marketed. The combination of DHPA and estradiol enantate has also been studied at other doses ranging from 75 to 200 mg DHPA and 5 to 50 mg estradiol enantate.
Algestone acetophenide
Algestone acetonide
Promegestone
Androstanolone propionate
Methandriol propionate
High-dose estrogen
Ethinylestradiol sulfonate
Nomegestrol acetate